News

Nuplazid’s Risks in Treating Parkinson’s Psychosis Don’t Appear Exceptionally High, Experts Say

The controversy surrounding Nuplazid (pimavanserin), Acadia Pharmaceuticals‘ approved treatment for psychosis in Parkinson’s patients, has made its way to scientific journals. But experts appear to take a more questioning view of the medication’s risks than that aired by general media. A clinical trial comparing the effectiveness and benefits of Nuplazid to…

New Biosensor May Shed Light on Molecular Processes Involved in Parkinson’s

New sensors with increased sensitivity and specificity to detect interactions between proteins, fat molecules, and other biological elements, represent a powerful tool to investigate mechanisms linked to human diseases, such as Alzheimer’s or Parkinson’s. Those findings were highlighted in the study “Resolving molecule-specific information in dynamic lipid membrane…

Smartphone App Designed to Help Early Detection of Parkinson’s Disease

European experts have developed a set of technology-based solutions for the early detection of Parkinson’s disease and improvement of patients’ quality of life. Led by Greek researchers at the Aristotle University of Thessaloniki, the four-year i-PROGNOSIS (Intelligent Parkinson eaRly detectiOn Guiding NOvel Supportive InterventionS) project is testing its first product…